Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , could offer a significant step forward for obesity treatment. Initial clinical trials have demonstrated https://bookmarkshut.com/story23020067/a-retatrutide-peptide-peptide-a-advancement-in-weight-management